Oncocyte Corp Schedules 2024 Annual Shareholder Meeting
Ticker: IMDX · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1642380
Sentiment: neutral
Topics: Oncocyte Corp, Annual Meeting, Proxy Statement, Shareholder Meeting, Virtual Meeting
TL;DR
<b>Oncocyte Corporation will hold its 2024 Annual Shareholder Meeting virtually on June 28, 2024, urging shareholders to return proxy cards.</b>
AI Summary
Oncocyte Corp (IMDX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Shareholders for Oncocyte Corporation will be held virtually on June 28, 2024, at 10:00 a.m. Pacific Time. Shareholders can attend the meeting online via a provided web link. The meeting will include a report on current operations and an opportunity for discussion. Shareholders are urged to sign and return their proxy cards to ensure their shares are represented, even if they plan to attend. Peter Hong serves as the Secretary of Oncocyte Corporation.
Why It Matters
For investors and stakeholders tracking Oncocyte Corp, this filing contains several important signals. This filing is a proxy statement, indicating the company is seeking shareholder votes on matters to be discussed at the annual meeting. The virtual format of the meeting aims to increase accessibility for shareholders to participate and engage with management.
Risk Assessment
Risk Level: — Oncocyte Corp shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Shareholders should review the proxy materials carefully to understand the proposals and vote accordingly.
Key Numbers
- 2024 — Annual Meeting Year (Year of the Annual Meeting of Shareholders.)
- June 28 — Meeting Date (Date of the 2024 Annual Meeting of Shareholders.)
- 10:00 a.m. — Meeting Time (Time of the 2024 Annual Meeting of Shareholders.)
Key Players & Entities
- Oncocyte Corporation (company) — Registrant and filer of the proxy statement.
- Peter Hong (person) — Secretary of Oncocyte Corporation.
- June 28, 2024 (date) — Date of the 2024 Annual Meeting of Shareholders.
- 10:00 a.m. Pacific Time (time) — Time of the 2024 Annual Meeting of Shareholders.
FAQ
When did Oncocyte Corp file this DEF 14A?
Oncocyte Corp filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Oncocyte Corp (IMDX).
Where can I read the original DEF 14A filing from Oncocyte Corp?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Oncocyte Corp.
What are the key takeaways from Oncocyte Corp's DEF 14A?
Oncocyte Corp filed this DEF 14A on April 29, 2024. Key takeaways: The 2024 Annual Meeting of Shareholders for Oncocyte Corporation will be held virtually on June 28, 2024, at 10:00 a.m. Pacific Time.. Shareholders can attend the meeting online via a provided web link.. The meeting will include a report on current operations and an opportunity for discussion..
Is Oncocyte Corp a risky investment based on this filing?
Based on this DEF 14A, Oncocyte Corp presents a moderate-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading Oncocyte Corp's DEF 14A?
Shareholders should review the proxy materials carefully to understand the proposals and vote accordingly. The overall sentiment from this filing is neutral.
How does Oncocyte Corp compare to its industry peers?
Oncocyte Corporation operates in the biotechnology sector, focusing on diagnostic solutions.
Are there regulatory concerns for Oncocyte Corp?
This filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the content of proxy statements.
Industry Context
Oncocyte Corporation operates in the biotechnology sector, focusing on diagnostic solutions.
Regulatory Implications
This filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the content of proxy statements.
What Investors Should Do
- Review the proxy statement for details on proposals and voting matters.
- Return the proxy card to ensure your vote is counted, even if attending virtually.
- Attend the virtual meeting on June 28, 2024, to participate in discussions.
Key Dates
- 2024-06-28: 2024 Annual Meeting of Shareholders — Shareholders will vote on company matters and hear operational updates.
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Shareholders.
Filing Stats: 4,695 words · 19 min read · ~16 pages · Grade level 12 · Accepted 2024-04-29 17:23:33
Filing Documents
- formdef14a.htm (DEF 14A) — 453KB
- formdef14a_001.jpg (GRAPHIC) — 7KB
- formdef14a_002.jpg (GRAPHIC) — 1KB
- formdef14a_003.jpg (GRAPHIC) — 100KB
- proxy_001.jpg (GRAPHIC) — 503KB
- proxy_002.jpg (GRAPHIC) — 713KB
- proxy_003.jpg (GRAPHIC) — 456KB
- 0001493152-24-017052.txt ( ) — 2907KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 15 PRINCIPAL SHAREHOLDERS 27 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 29 PROPOSAL NO. 2: RATIFICATION OF APPOINTMENT OF ACCOUNTING FIRM 31 REPORT OF THE AUDIT COMMITTEE ON THE AUDIT OF OUR CONSOLIDATED FINANCIAL STATEMENTS 33 PROPOSAL NO. 3: SAY ON PAY PROPOSAL 34 DELINQUENT SECTION 16(a) REPORTS 35 PROPOSALS OF SHAREHOLDERS 35 ANNUAL REPORT 35 HOW TO ATTEND THE ANNUAL MEETING 36 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Proxy Statement contains forward-looking compensation decisions, the composition of our board of directors and its committees, and other future events. You can identify forward-looking “intend,” “believe,” “continue,” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. We have based these forward-looking business, results of operations and financial condition. The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in Item 1A, “Risk Factors,” and elsewhere, in our Annual Report on Form 10-K for the year ended December 31, 2023, as well as the other reports we file with the Securities and Exchange Commission. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those expressed or implied in the for